• English
    • العربية
  • English 
    • English
    • العربية
  • Login
View Item 
  •   DSpace Home
  • AQU Research Network Clusters
  • AQU researchers publications
  • View Item
  •   DSpace Home
  • AQU Research Network Clusters
  • AQU researchers publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABLand BCR-ABL-T315I

Thumbnail
View/Open
RES_14_JOURNAL_paper_3.pdf (712.9Kb)
Date
2012-09-17
Author
Mian, Afsar Ali
Metodieva, Anna
Badura, Susanne
Khateb, Mamduh
Najajreh, Yousef
Ottmann, Oliver Gerhard
Mahajna, Jamal
Ruthardt, Martin
Metadata
Show full item record
Abstract
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR/ABL-kinase “escapes” the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the ‘gatekeeper’ mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia. Methods: The efficacy of this approach on the leukemogenic potential of BCR/ABL was studied in Ba/F3 cells, primary murine bone marrow cells, and untransformed Rat-1 fibroblasts expressing BCR/ABL or BCR/ABL-T315I as well as in patient-derived long-term cultures (PDLTC) from Ph + ALL-patients. Results: Here, we show that GNF-2 increased the effects of AKIs on unmutated BCR/ABL. Interestingly, the combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic manner. Conclusions: Our observations establish a new approach for the molecular targeting of BCR/ABL and its resistant mutants using a combination of AKIs and allosteric inhibitors.
URI
https://dspace.alquds.edu/handle/20.500.12213/839
Collections
  • AQU researchers publications [753]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV